Oncology

This slide deck aims to provide an overview of metastatic breast cancer, including subtypes and prognoses, and a summary of systemic and targeted treatments. Learn more.

This slide deck provides an overview of non-endocrine, targeted treatment options in HR+, HER2- MBC, including information on the MOA of different therapy classes and the phase 2/3 clinical studies for approved therapies in this setting.

This slide deck provides an overview of the ER+, HER2- advanced breast cancer landscape, including information on ER targeted therapies, mechanisms of resistance to ET +/- CDK4/6 inhibitors, & scientific advancements in the form of next-generation ETs.

This infographic is intended to educate healthcare providers on the heterogeneity of HR+, HER2- metastatic breast cancer, factors more likely to confer a poorer prognosis, and information on the standard first-line treatment for patients.

This infographic is intended to educate healthcare providers on the unmet need for patients who progress on 1L standard of care for HR+, HER2- metastatic breast cancer, and includes clinical research to support treatment decisions in the 2L setting.

This infographic introduces ER+, HER2-, ABC, how the estrogen pathway is being targeted by 3 classes of endocrine therapies (ET), and the unmet needs that remain

This infographic provides an overview of resistance mechanisms against ET; highlighting ESR1 mutations, including when and how to test for these mutations in ER+, HER2-, ABC

This infographic summarizes the complex treatment landscape after progression or recurrence on ET+ CKD4/6 inhibitors in ER+, HER2-, ABC and the limitations for the 3 main classes of approved ETs

This infographic provides an overview of the approved and investigational ET classes in ER+, HER2-, ABC; highlights the potential benefits of next-generation ETs, resulting in more potent endocrine pathway antagonism